Phio Pharmaceuticals Corp (PHIO)

$2.16 +0.03 (1.30%)
Market Cap 12.48M
Revenue (ttm) 0.00
Net Income (ttm) -7.15M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 59,884
Avg Vol 1,155,282
Day's Range N/A - N/A
Shares Out 5.73M
Stochastic %K 24%
Beta 0.89
Analysts Sell
Price Target $14.00

Company Profile

Phio Pharmaceuticals Corp., a a clinical stage biotechnology company, engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma a...

Industry: Biotechnology
Sector: Healthcare
Phone: 508 767 3861
Address:
11 Apex Drive, Suite 300A PMB 2006, Marlborough, United States
PitaPierogi
PitaPierogi Sep. 16 at 3:40 PM
$PHIO Phio (PHIO) is currently in Phase 1, 5th cohort. A lot of people think buyouts only happen once a drug is in Phase 2 or 3, but there are plenty of examples of Phase 1 acquisitions in recent years: Capstan Therapeutics → AbbVie (2025): lead in-vivo CAR-T in Phase 1, deal worth up to ~$2.1B. Scorpion Therapeutics (program) → Eli Lilly (2025): PI3Kα inhibitor in Phase 1/2, deal up to ~$2.5B. IDRx → GSK (2025): KIT TKI in Phase I/Ib, ~$1.15B with $1B upfront. Curon Biopharma asset (CN201) → Merck (2024–25): bispecific in Phase 1, ~$1.3B total deal. So yes — companies do get scooped up while still in Phase 1 if (a) mechanism looks differentiated, (b) early human data show clean safety/PK with a hint of efficacy, and (c) the buyer has a pipeline gap to fill.
1 · Reply
PitaPierogi
PitaPierogi Sep. 16 at 2:30 PM
$PHIO they set themselves up for life. They have great confidence in the product. Buy and hold. Buyout imminent.
1 · Reply
Stayou
Stayou Sep. 16 at 12:39 PM
$PHIO Look at the SEC-Filings. The whole board of directors bought shares these days. They believe in their Produkts!!!
0 · Reply
nepepe
nepepe Sep. 16 at 10:55 AM
$PHIO 👀
0 · Reply
PitaPierogi
PitaPierogi Sep. 15 at 3:01 PM
$PHIO chess pieces are being moved into position for something big.... ceo knows something. Big move.
0 · Reply
bgmorgan88
bgmorgan88 Sep. 15 at 12:05 PM
$PHIO buy and hold time.
0 · Reply
NoFooling
NoFooling Sep. 13 at 11:11 PM
$PHIO
0 · Reply
phio
phio Sep. 13 at 10:30 PM
$PHIO Was there anything said at the Wainwright conference?
0 · Reply
TechnicalChartSetups
TechnicalChartSetups Sep. 13 at 5:09 AM
MITQ is a top squeeze candidate for next week as low float theme continues, could be the next 200-300%+ runner. Also watching: $MODD $SGMD $BLNE $PHIO
0 · Reply
Avennite
Avennite Sep. 12 at 6:40 PM
$PHIO I'm not really expecting much movement till cohort 5 enrollment is completed. Then some additional time for results to be reviewed. My Guess is end of November early December.
3 · Reply
Latest News on PHIO
Phio Pharmaceuticals to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Sep 3, 2025, 7:45 AM EDT - 13 days ago

Phio Pharmaceuticals to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Phio Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 14, 2025, 4:15 PM EDT - 4 weeks ago

Phio Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

Phio Pharmaceuticals Announces Exercise of Warrants for Approximately $2.5 Million Gross Proceeds

Jul 25, 2025, 3:04 PM EDT - 7 weeks ago

Phio Pharmaceuticals Announces Exercise of Warrants for Approximately $2.5 Million Gross Proceeds

Phio Pharmaceuticals Announces Pathology Results for Four of Five Patients in Fourth Cohort

Jul 25, 2025, 12:36 PM EDT - 7 weeks ago

Phio Pharmaceuticals Announces Pathology Results for Four of Five Patients in Fourth Cohort

Phio Pharmaceuticals Announces Agreement with U.S. Manufacturing Source for Drug Substance

Jul 25, 2025, 7:45 AM EDT - 7 weeks ago

Phio Pharmaceuticals Announces Agreement with U.S. Manufacturing Source for Drug Substance

Phio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Clinical Trial to Fifth Dose Escalation Cohort

Jun 25, 2025, 7:45 AM EDT - 2 months ago

Phio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Clinical Trial to Fifth Dose Escalation Cohort

Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

Jun 24, 2025, 7:45 AM EDT - 3 months ago

Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

Phio Pharmaceuticals Announces Strategic Initiative to Create Awareness of the Comprehensive INTASYL siRNA Portfolio

Jun 6, 2025, 7:45 AM EDT - 3 months ago

Phio Pharmaceuticals Announces Strategic Initiative to Create Awareness of the Comprehensive INTASYL siRNA Portfolio

Phio Pharmaceuticals Announces Participation in the Sidoti Micro-Cap Virtual Investor Conference

May 19, 2025, 7:45 AM EDT - 4 months ago

Phio Pharmaceuticals Announces Participation in the Sidoti Micro-Cap Virtual Investor Conference

Phio Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

May 15, 2025, 4:15 PM EDT - 4 months ago

Phio Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

Phio Pharmaceuticals Announces Positive Pathology Results in Third Cohort in INTASYL PH-762 Skin Cancer Clinical Trial

May 7, 2025, 7:45 AM EDT - 4 months ago

Phio Pharmaceuticals Announces Positive Pathology Results in Third Cohort in INTASYL PH-762 Skin Cancer Clinical Trial

Phio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Study to Fourth Dose Escalation Cohort

Apr 9, 2025, 7:45 AM EDT - 5 months ago

Phio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Study to Fourth Dose Escalation Cohort

Phio Pharmaceuticals Announces Podium Presentations on INTASYL siRNA Lead Product Candidates PH-762 and PH-894

Apr 3, 2025, 7:45 AM EDT - 5 months ago

Phio Pharmaceuticals Announces Podium Presentations on INTASYL siRNA Lead Product Candidates PH-762 and PH-894

Phio Pharmaceuticals Reports 2024 Year End Financial Results and Provides Business Update

Mar 31, 2025, 4:00 PM EDT - 6 months ago

Phio Pharmaceuticals Reports 2024 Year End Financial Results and Provides Business Update

American Academy of Dermatology Awards Podium Presentation to Phio Pharmaceutical's Clinical Research at 2025 Annual Meeting

Mar 10, 2025, 7:45 AM EDT - 6 months ago

American Academy of Dermatology Awards Podium Presentation to Phio Pharmaceutical's Clinical Research at 2025 Annual Meeting

Phio Pharmaceuticals Announces Completion of Enrollment in Third Safety Cohort in PH-762 Phase 1b Dose-Escalation Study

Mar 5, 2025, 7:45 AM EST - 6 months ago

Phio Pharmaceuticals Announces Completion of Enrollment in Third Safety Cohort in PH-762 Phase 1b Dose-Escalation Study

Phio Pharmaceuticals Announces Appointment of David H. Deming to Board of Directors

Feb 20, 2025, 7:45 AM EST - 7 months ago

Phio Pharmaceuticals Announces Appointment of David H. Deming to Board of Directors

Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

Jan 22, 2025, 7:00 AM EST - 8 months ago

Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

Phio Pharmaceuticals Announces Closing of $1.83 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jan 21, 2025, 4:15 PM EST - 8 months ago

Phio Pharmaceuticals Announces Closing of $1.83 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Phio Pharmaceuticals Announces $1.83 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jan 16, 2025, 1:00 PM EST - 8 months ago

Phio Pharmaceuticals Announces $1.83 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Phio Pharmaceuticals Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jan 15, 2025, 7:00 AM EST - 8 months ago

Phio Pharmaceuticals Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Phio Pharmaceuticals Announces $3.19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jan 14, 2025, 7:00 AM EST - 8 months ago

Phio Pharmaceuticals Announces $3.19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Cancer-Focused Phio Pharmaceuticals Stock Gains 300% On Monday - Here's Why

Jan 13, 2025, 12:45 PM EST - 8 months ago

Cancer-Focused Phio Pharmaceuticals Stock Gains 300% On Monday - Here's Why

Phio Pharmaceuticals Announces Promising Results of Second Cohort from Its Ongoing Clinical Study of PH-762

Jan 13, 2025, 7:45 AM EST - 8 months ago

Phio Pharmaceuticals Announces Promising Results of Second Cohort from Its Ongoing Clinical Study of PH-762

Phio Pharmaceuticals Announces Publication in Clinical, Cosmetic and Investigational Dermatology

Jan 2, 2025, 7:45 AM EST - 9 months ago

Phio Pharmaceuticals Announces Publication in Clinical, Cosmetic and Investigational Dermatology

Phio Pharmaceuticals Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Dec 23, 2024, 1:15 PM EST - 9 months ago

Phio Pharmaceuticals Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Phio Pharmaceuticals Announces $1.15 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Dec 19, 2024, 2:28 PM EST - 9 months ago

Phio Pharmaceuticals Announces $1.15 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Phio Pharmaceuticals Announces Positive Safety Monitoring Committee (SMC) Recommendation to Continue to Third Dose Cohort in its Clinical Study of PH-762

Dec 19, 2024, 7:45 AM EST - 9 months ago

Phio Pharmaceuticals Announces Positive Safety Monitoring Committee (SMC) Recommendation to Continue to Third Dose Cohort in its Clinical Study of PH-762

Phio Pharmaceuticals Announces Publication in Frontiers in Immunology

Dec 12, 2024, 9:21 AM EST - 9 months ago

Phio Pharmaceuticals Announces Publication in Frontiers in Immunology

Phio Pharmaceuticals is a Finalist for the Technology Disruptor of the Year Award

Dec 10, 2024, 7:45 AM EST - 10 months ago

Phio Pharmaceuticals is a Finalist for the Technology Disruptor of the Year Award

Phio Pharmaceuticals Announces Completion of Enrollment in Second Cohort in Phase 1b Dose-Escalating Clinical Study

Nov 19, 2024, 7:45 AM EST - 10 months ago

Phio Pharmaceuticals Announces Completion of Enrollment in Second Cohort in Phase 1b Dose-Escalating Clinical Study

Phio Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 14, 2024, 5:47 PM EST - 10 months ago

Phio Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

Phio Pharmaceuticals Announces Upcoming Presentation at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Nov 7, 2024, 10:00 AM EST - 11 months ago

Phio Pharmaceuticals Announces Upcoming Presentation at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Correction to Registration Link to Access Phio Pharmaceuticals' Presentation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

Oct 18, 2024, 1:30 PM EDT - 11 months ago

Correction to Registration Link to Access Phio Pharmaceuticals' Presentation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-deal Roadshow Series

Oct 18, 2024, 8:00 AM EDT - 11 months ago

Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-deal Roadshow Series

Phio Pharmaceuticals Presenting Data on Its INSTAYL Compound PH-894 at ASGCT's 2024 Advancing Gene and Cell Therapies for Cancer Conference

Oct 16, 2024, 8:00 AM EDT - 11 months ago

Phio Pharmaceuticals Presenting Data on Its INSTAYL Compound PH-894 at ASGCT's 2024 Advancing Gene and Cell Therapies for Cancer Conference

Phio Announces Data Showcasing INTASYL's Role in Helping Immune Cells Target and Kill Cancer Cells

Oct 7, 2024, 8:00 AM EDT - 1 year ago

Phio Announces Data Showcasing INTASYL's Role in Helping Immune Cells Target and Kill Cancer Cells

INTASYL Technology and Compounds to be Focus of Presentation at 20th Annual Meeting of Oligonucleotide Therapeutics Society

Sep 25, 2024, 8:00 AM EDT - 1 year ago

INTASYL Technology and Compounds to be Focus of Presentation at 20th Annual Meeting of Oligonucleotide Therapeutics Society

Phio Pharmaceuticals Announces Presentation at the 9th Annual CAR-TCR Summit in Boston, MA

Sep 16, 2024, 8:00 AM EDT - 1 year ago

Phio Pharmaceuticals Announces Presentation at the 9th Annual CAR-TCR Summit in Boston, MA

Phio Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Sep 9, 2024, 7:00 AM EDT - 1 year ago

Phio Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Phio Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 14, 2024, 5:00 PM EDT - 1 year ago

Phio Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

Phio Pharmaceuticals Announces Exploratory Collaboration with a Luxury Skin Care Company for Phio's Patented INTASYL Compound

Aug 6, 2024, 8:00 AM EDT - 1 year ago

Phio Pharmaceuticals Announces Exploratory Collaboration with a Luxury Skin Care Company for Phio's Patented INTASYL Compound

Phio Pharmaceuticals Announces New Chief Financial Officer

Aug 1, 2024, 8:00 AM EDT - 1 year ago

Phio Pharmaceuticals Announces New Chief Financial Officer

Phio Pharmaceuticals Announces Exercise of Warrants for $3.1 Million Gross Proceeds

Jul 12, 2024, 8:00 AM EDT - 1 year ago

Phio Pharmaceuticals Announces Exercise of Warrants for $3.1 Million Gross Proceeds

Phio Pharmaceuticals Announces Addition of Clinical Trial Site for its Phase 1b study of PH-762

Jul 8, 2024, 8:00 AM EDT - 1 year ago

Phio Pharmaceuticals Announces Addition of Clinical Trial Site for its Phase 1b study of PH-762

Phio Pharmaceuticals Terminates Share Purchase Agreement with Triton Funds

Jul 5, 2024, 8:00 AM EDT - 1 year ago

Phio Pharmaceuticals Terminates Share Purchase Agreement with Triton Funds

Phio Pharmaceuticals Announces Reverse Stock Split

Jul 2, 2024, 11:45 AM EDT - 1 year ago

Phio Pharmaceuticals Announces Reverse Stock Split

Phio Pharmaceuticals Announces New Patent for INTASYL Compound That Targets Photo-aging

Jun 18, 2024, 7:30 AM EDT - 1 year ago

Phio Pharmaceuticals Announces New Patent for INTASYL Compound That Targets Photo-aging

Phio Pharmaceuticals Announces Positive Recommendation from Safety Monitoring Committee (SMC) of Phase 1b Clinical Study of Phio's Lead Compound PH-762

May 28, 2024, 7:30 AM EDT - 1 year ago

Phio Pharmaceuticals Announces Positive Recommendation from Safety Monitoring Committee (SMC) of Phase 1b Clinical Study of Phio's Lead Compound PH-762

Phio Pharmaceuticals Announces Presentation at the Annual Meeting of the American Society of Clinical Oncology (ASCO)

May 23, 2024, 5:00 PM EDT - 1 year ago

Phio Pharmaceuticals Announces Presentation at the Annual Meeting of the American Society of Clinical Oncology (ASCO)

PitaPierogi
PitaPierogi Sep. 16 at 3:40 PM
$PHIO Phio (PHIO) is currently in Phase 1, 5th cohort. A lot of people think buyouts only happen once a drug is in Phase 2 or 3, but there are plenty of examples of Phase 1 acquisitions in recent years: Capstan Therapeutics → AbbVie (2025): lead in-vivo CAR-T in Phase 1, deal worth up to ~$2.1B. Scorpion Therapeutics (program) → Eli Lilly (2025): PI3Kα inhibitor in Phase 1/2, deal up to ~$2.5B. IDRx → GSK (2025): KIT TKI in Phase I/Ib, ~$1.15B with $1B upfront. Curon Biopharma asset (CN201) → Merck (2024–25): bispecific in Phase 1, ~$1.3B total deal. So yes — companies do get scooped up while still in Phase 1 if (a) mechanism looks differentiated, (b) early human data show clean safety/PK with a hint of efficacy, and (c) the buyer has a pipeline gap to fill.
1 · Reply
PitaPierogi
PitaPierogi Sep. 16 at 2:30 PM
$PHIO they set themselves up for life. They have great confidence in the product. Buy and hold. Buyout imminent.
1 · Reply
Stayou
Stayou Sep. 16 at 12:39 PM
$PHIO Look at the SEC-Filings. The whole board of directors bought shares these days. They believe in their Produkts!!!
0 · Reply
nepepe
nepepe Sep. 16 at 10:55 AM
$PHIO 👀
0 · Reply
PitaPierogi
PitaPierogi Sep. 15 at 3:01 PM
$PHIO chess pieces are being moved into position for something big.... ceo knows something. Big move.
0 · Reply
bgmorgan88
bgmorgan88 Sep. 15 at 12:05 PM
$PHIO buy and hold time.
0 · Reply
NoFooling
NoFooling Sep. 13 at 11:11 PM
$PHIO
0 · Reply
phio
phio Sep. 13 at 10:30 PM
$PHIO Was there anything said at the Wainwright conference?
0 · Reply
TechnicalChartSetups
TechnicalChartSetups Sep. 13 at 5:09 AM
MITQ is a top squeeze candidate for next week as low float theme continues, could be the next 200-300%+ runner. Also watching: $MODD $SGMD $BLNE $PHIO
0 · Reply
Avennite
Avennite Sep. 12 at 6:40 PM
$PHIO I'm not really expecting much movement till cohort 5 enrollment is completed. Then some additional time for results to be reviewed. My Guess is end of November early December.
3 · Reply
HeyItsSnorlax
HeyItsSnorlax Sep. 11 at 7:36 PM
ZKIN stock will have a huge short squeeze with the 3M float locked and multiple upcoming crypto catalysts including the launch of their own cryptocurrency platform. They already have amazing financials ! $INTS $PRPO $INTS $AZI $PHIO watching into close
0 · Reply
DosGatos
DosGatos Sep. 11 at 6:54 PM
$PHIO oh yea their 1000th presentation Im sure it will make a big difference!
1 · Reply
BrocM
BrocM Sep. 11 at 6:42 PM
$PHIO deserves some mainstream recognition. I'm sure their patients who have been cured of cancer would agree. Let's increase awareness of this amazing company! https://beyondspx.com/quote/PHIO/analysis/phio-pharmaceuticals-intasyl-s-precision-strike-in-immuno-oncology-nasdaq-phio $TSLA $DJT $WBD
0 · Reply
BrocM
BrocM Sep. 11 at 5:38 PM
$GALT People are starting to notice, $PHIO is heating up. 100% tumor clearance in multiple patients is not an insignificant result, in fact this could change the industry. Future billion dollar company i the making IMHO. $WLDS $ISPC
1 · Reply
BrocM
BrocM Sep. 11 at 3:00 PM
$PHIO Get your shares under 3 while you can, this will pop off past it's 14 dollar PT very soon (set by HC Wainwright & Co). When you cure multiple people of cancer in the first phase of clinical trials, you only have one way to go. ⬆️ $ASST $OPEN $GLXY
0 · Reply
Pratik2024
Pratik2024 Sep. 11 at 12:49 PM
$HOLO $HOTH $PHIO Excellent HOTH
0 · Reply
Avennite
Avennite Sep. 11 at 12:32 PM
$PHIO Does anyone have a link to yesterdays presentation?
1 · Reply
Telos52
Telos52 Sep. 11 at 10:20 AM
$PHIO
0 · Reply
ExplosiveGainz
ExplosiveGainz Sep. 11 at 3:32 AM
$PHIO looks like theres a big run coming soon.
0 · Reply
Pratik2024
Pratik2024 Sep. 10 at 9:09 PM
$HOLO $HOTH $PHIO HOTH big news. I see moon
0 · Reply
BrocM
BrocM Sep. 10 at 7:55 PM
$PHIO Cohort 5 results will send this flying, especially if there are more 100% tumor clearances, which is very likely with the highest dosage. DD: https://beyondspx.com/quote/PHIO/analysis/phio-pharmaceuticals-intasyl-s-precision-strike-in-immuno-oncology-nasdaq-phio $ASST $ORCL $WLDS
0 · Reply
BrocM
BrocM Sep. 10 at 6:42 PM
$PHIO Wonder what they're talking about at the presentation 😌 Probably about how this is going to revolutionize the skin cancer industry and help millions of people in the upcoming decades. $ASST $WLDS $ORBS
0 · Reply